Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA

References

• Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol. Rec.82(12), 93–104 (2007).
   Google Scholar
• Preventing pneumococcal disease among infants and young children. Recommendations of the AdvisoryCommittee on Immunization Practices (ACIP). MMWR Recomm. Rep.49(RR-9), 1–35 (2000).
   PubMedGoogle Scholar
• Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect. Dis.2(1), 25–32 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA285(13), 1729–1735 (2001).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med.337(14), 970–976 (1997).
   PubMed Web of Science ®Google Scholar
• Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. Lancet Neurol.5(2), 123–129 (2006).
   PubMed Web of Science ®Google Scholar
• Goetghebuer T, West TE, Wermenbol V et al. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae type b in children in The Gambia. Trop. Med. Int. Health5(3), 207–213 (2000).
   PubMed Web of Science ®Google Scholar
• Kastenbauer S, Pfister H-W. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain126(Pt 5), 1015–1025 (2003).
   PubMed Web of Science ®Google Scholar
• Chavez-Bueno S, McCracken GH Jr. Bacterial meningitis in children. Pediatr. Clin. North Am.52(3), 795–810, vii (2005).
   PubMed Web of Science ®Google Scholar
• Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat. Rep.53(17), 1–89 (2005).
   PubMedGoogle Scholar
• Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? Lancet Infect. Dis.6(3), 150–161 (2006).
   PubMed Web of Science ®Google Scholar
• Michelow IC, Olsen K, Lozano J et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics113(4), 701–707 (2004).
   PubMed Web of Science ®Google Scholar
• Drummond P, Clark J, Wheeler J, Galloway A, Freeman R, Cant A. Community acquired pneumonia – a prospective UK study. Arch. Dis. Child.83(5), 408–412 (2000).
   PubMed Web of Science ®Google Scholar
• Whitney CG. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65. Geriatrics58(10), 20–22, 25 (2003).
   Google Scholar
• Marston BJ, Plouffe JF, File TM Jr et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch. Intern. Med.157(15), 1709–1718 (1997).
   PubMed Web of Science ®Google Scholar
• Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am. J. Public Health90(2), 223–229 (20002000)
   PubMed Web of Science ®Google Scholar
• Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a children’s hospital emergency department and urgent care center. Arch. Pediatr. Adolesc. Med.158(7), 671–675 (2004).
   PubMedGoogle Scholar
• Kaplan B, Wandstrat TL, Cunningham JR. Overall cost in the treatment of otitis media. Pediatr. Infect. Dis. J.16(2 Suppl.), S9–S11 (1997).
   Google Scholar
• Subcommittee on Management of Acute Otitis Media. Diagnosis and management of acute otitis media. Pediatrics113(5), 1451–1465 (2004).
   PubMed Web of Science ®Google Scholar
• Auinger P, Lanphear BP, Kalkwarf HJ, Mansour ME. Trends in otitis media among children in the United States. Pediatrics112(3 Pt 1), 514–520 (2003).
   PubMed Web of Science ®Google Scholar
• Dowell SF, Schwartz B, Phillips WR. Appropriate use of antibiotics for URIs in children: part I. Otitis media and acute sinusitis. The Pediatric URI Consensus Team. Am. Fam. Physician58(5), 1113–1118; 1123 (1998).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr. Opin. Otolaryngol. Head Neck Surg.12(6), 488–494 (2004).
   PubMedGoogle Scholar
• Levine OS, O’Brien KL, Knoll M et al. Pneumococcal vaccination in developing countries. Lancet367(9526), 1880–1882 (2006).
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis.30(1), 100–121 (2000).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Austrian R, Lee CJ et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J. Infect. Dis.148(6), 1136–1159 (1983).
   PubMed Web of Science ®Google Scholar
• Sniadack DH, Schwartz B, Lipman H et al. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children – implications for vaccine strategies. Pediatr. Infect. Dis. J.14(6), 503–510 (1995).
   PubMed Web of Science ®Google Scholar
• CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm. Rep.46(RR8), 1–24 (1997).
   Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur. J. Epidemiol.19(4), 353–363 (2004).
   PubMed Web of Science ®Google Scholar
• WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Technical Report Series64–98 (>20052005).
   Google Scholar
• Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med.348(18), 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Edwards KM, Griffin MR. Great expectations for a new vaccine. N. Engl. J. Med.349(14), 1312–1314 (2003).
   Google Scholar
• Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J. Infect. Dis.171(4), 885–889 (1995).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine21(17–18), 1815–1825 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis.185(7), 927–936 (2002).
   PubMed Web of Science ®Google Scholar
• Jodar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine21(23), 3265–3272 (2003).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J.19, 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Cutts FT, Zaman SM, Enwere G et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet365(9465), 1139–1146 (2005).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med349(14), 1341–1348 (2003).
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet367(9512), 740–748 (2006).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Moulton LH, Reid R et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet362(9381), 355–361 (2003).
   PubMed Web of Science ®Google Scholar
• Hansen J, Black S, Shinefield H et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr. Infect. Dis. J.25(9), 779–781 (2006).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Klugman KP. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat. Med.10(8), 811–813 (2004).
   PubMed Web of Science ®Google Scholar
• Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis.37(9), 1155–1164 (2003).
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J.22(1), 10–16 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Sikuler-Cohen M, Zamir O, Janco J, Givon-Lavi N, Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr. Infect. Dis. J.20(10), 951–958 (2001).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J.22(6), 532–540 (2003).
   PubMed Web of Science ®Google Scholar
• Wise RP, Iskander J, Pratt RD et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA292(14), 1702–1710 (2004).
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Martin SW, Smith P, Moran J, Schwartz B. Uptake of pneumococcal conjugate vaccine among children in the United States, 2000–2004. Presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD5). Alice Springs, Australia, 2–6 April 2006.
   Google Scholar
• Schaffer SJ, Szilagyi PG, Shone LP et al. Physician perspectives regarding pneumococcal conjugate vaccine. Pediatrics110(6), e68 (2002).
   Google Scholar
• Ray WA. Policy and program analysis using administrative databases. Ann. Intern. Med.127(8 Pt 2), 712–718 (1997).
   PubMed Web of Science ®Google Scholar
• Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. Am. J. Epidemiol.133(4), 323–331 (1991).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med.354(14), 1455–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Lafleur BJ, Szilagyi PG et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics114(3), 755–761 (2004).
   PubMed Web of Science ®Google Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54(36), 893–897 (2005).
   PubMedGoogle Scholar
• Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA295(14), 1668–1674 (2006).
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297(16), 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, Vugia DJ. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco county, California. Ann. Intern. Med.132(3), 182–190 (2000).
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr. Infect. Dis. J.24(5), 410–416 (2005).
   PubMed Web of Science ®Google Scholar
• Flannery B, Heffernan RT, Harrison LH et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann. Intern. Med.144(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Halasa NB, Shankar SM, Talbot TR et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis.44(11), 1428–1433 (2007).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet369(9568), 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Heffernan RT, Barrett NL, Gallagher KM et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J. Infect. Dis.191(12), 2038–2045 (2005).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Whitney CG, Yu O et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia. Presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD5). Alice Springs, Australia, 2–6 April 2006.
   Google Scholar
• Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics118(3), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics119(4), 707–715 (2007).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr. Infect. Dis. J.23(9), 824–828 (2004).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA298(15), 1772–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerging Infect. Dis.5(3), 336–345 (1999).
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis.196(9), 1346–1354 (2007).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.26(6), 468–472 (2007).
   PubMed Web of Science ®Google Scholar
• Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis.192(11), 1988–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Kim NH, Kim SH, Lee JA, Choi EH, Lee HJ. Changes of serotype distribution of Streptococcus pneumonia isolated from children in Korea over a 15 year-period, 1991–2005. Presented at: Annual Meeting of the Infectious Disease Society of America. Toronto, ON, Canada, 12–15 October 2006 (Abstract 645).
   Google Scholar